Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Enterprise Value (2016 - 2025)

ImmunityBio (IBRX) has disclosed Enterprise Value for 12 consecutive years, with -$241.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 62.54% to -$241.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$241.9 million, a 62.54% decrease, with the full-year FY2025 number at -$241.9 million, down 62.54% from a year prior.
  • Enterprise Value was -$241.9 million for Q4 2025 at ImmunityBio, up from -$256.9 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$49.0 million in Q2 2023 to a low of -$318.9 million in Q4 2021.
  • A 5-year average of -$153.2 million and a median of -$139.1 million in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 65.6% in 2022, then crashed 342.61% in 2024.
  • ImmunityBio's Enterprise Value stood at -$318.9 million in 2021, then surged by 65.6% to -$109.7 million in 2022, then tumbled by 141.99% to -$265.4 million in 2023, then skyrocketed by 43.92% to -$148.8 million in 2024, then plummeted by 62.54% to -$241.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Enterprise Value are -$241.9 million (Q4 2025), -$256.9 million (Q3 2025), and -$152.7 million (Q2 2025).